Equities

Financiere de Tubize SA

Financiere de Tubize SA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)112.60
  • Today's Change-0.600 / -0.53%
  • Shares traded5.20k
  • 1 Year change+59.04%
  • Beta0.6002
Data delayed at least 15 minutes, as of Jul 17 2024 13:10 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Financiere de Tubize SA is a Belgium-based holding company. The Company holds minor capital in UCB SA. UCB is a Belgian pharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. UCB, together with its subsidiaries, has research and development facilities in Belgium, Germany, Japan, the United Kingdom and the United States. The Company promotes the development of a sustainable biopharma ecosystem in Belgium and possibly in other geographic areas relevant to UCB.

  • Revenue in EUR (TTM)0.00
  • Net income in EUR88.15m
  • Incorporated1928
  • Employees--
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Avidity Biosciences Inc9.97m-209.82m4.55bn253.00--5.37--455.83-2.95-2.950.14088.690.0139----42,964.43-29.22-31.61-31.71-34.45-----2,103.78-1,540.50----0.00--3.6490.71-21.97--143.89--
Apellis Pharmaceuticals Inc480.84m-382.86m4.58bn702.00--18.71--9.53-3.46-3.464.332.200.57880.57473.50746,538.40-46.09-73.88-57.28-90.0386.47---79.62-326.493.02-38.720.6087--425.83--18.94------
Rohto Pharmaceutical Co Ltd1.57bn179.25m4.63bn7.26k25.013.1319.932.95135.21135.211,183.751,079.720.82592.594.1737,310,920.009.578.5413.0211.7958.0758.5911.5910.301.93--0.061419.3913.488.0917.2825.855.2018.61
Richter Gedeon Vegyeszeti Gyar Nyrt2.04bn479.14m4.65bn11.60k9.591.517.602.281,020.541,020.534,335.986,494.050.57241.464.0568,856,070.0013.6211.6415.3413.2867.1158.1823.8018.933.08--0.015339.940.299312.57-6.0535.0615.5933.94
Siegfried Holding AG1.31bn115.05m4.66bn3.93k38.285.0923.403.5726.2826.28298.23197.490.69582.273.14323,288.606.176.517.677.9825.2023.248.869.061.397.930.346815.263.419.87-28.1618.3417.956.72
Laboratorios Farmaceuticos ROVI SA779.05m137.84m4.68bn2.11k33.298.6529.336.012.602.6014.7410.030.93640.98385.34369,045.0016.5618.9022.7525.5858.0159.8217.6920.130.771812.800.13534.371.4422.30-14.6956.9315.8469.11
GlaxoSmithKline Pharmaceuticals Limited379.35m64.80m4.86bn3.21k74.9824.8867.0512.8134.8234.82203.88104.931.002.7116.6710,755,860.0017.1411.0129.2617.8861.3655.7717.0812.251.49466.450.0104192.076.212.00-2.915.78-36.029.86
Hikma Pharmaceuticals Plc2.64bn174.36m4.88bn8.97k28.062.4113.901.850.65950.65959.977.670.62841.763.67247,297.504.208.195.7211.3048.9450.296.6813.770.90297.680.350336.7114.226.731.06-7.597.9714.03
Krka d.d. Novo Mesto1.83bn323.81m4.90bn11.80k14.262.0411.502.6710.4810.4859.3673.170.65281.373.57157,225.7011.5112.6413.6815.1255.9957.2917.6418.712.8866.700.005659.215.186.28-13.5812.458.3518.57
Organon & Co5.82bn960.64m4.91bn10.00k5.10110.924.150.84324.084.0824.710.18760.56032.184.24634,700.009.2416.5311.7920.9759.0465.1216.5026.791.152.360.99458.251.44-8.5211.56-13.8320.72--
BridgeBio Pharma Inc200.57m-493.87m5.02bn550.00------25.04-3.23-3.231.29-5.610.2964----397,449.10-74.13-72.44-90.19-89.7298.9194.41-250.09-1,225.66---11.482.53---88.02---33.67---40.94--
Financiere de Tubize SA0.0088.15m5.04bn--57.162.8057.16--1.981.980.0040.36----------7.04--7.24------145.70----0.042220.94----3.50-20.93--11.61
Aspen Pharmacare Holdings Limited2.17bn246.95m5.30bn8.61k21.371.2216.672.4510.9610.9696.12192.690.32861.283.334,958,198.003.753.544.424.4445.1548.7211.4011.581.096.500.296719.475.451.22-19.42-1.441.001.66
Data as of Jul 17 2024. Currency figures normalised to Financiere de Tubize SA's reporting currency: Euro EUR

Institutional shareholders

1.14%Per cent of shares held by top holders
HolderShares% Held
BNP Paribas Asset Management Europe SASas of 29 Nov 202397.71k0.22%
Investor Asset Management BVas of 05 Jul 202482.79k0.19%
Capricorn Venture Partners NV (Investment Management)as of 30 Apr 202470.09k0.16%
Value Square NVas of 30 Apr 202456.94k0.13%
Sunline Pte Ltd.as of 28 Mar 202456.33k0.13%
Econopolis Wealth Management NVas of 30 Jun 202340.00k0.09%
Degroof Petercam Asset Management SAas of 28 Mar 202432.95k0.07%
KBC Asset Management NVas of 31 Dec 202325.81k0.06%
Bank Nagelmackers NVas of 11 Jul 202424.12k0.05%
Richelieu Gestionas of 28 Mar 202420.30k0.05%
More ▼
Data from 30 Jun 2023 - 11 Jul 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.